Omnicell Inc. Stock
Omnicell Inc. Stock
Omnicell Inc. took a tumble today and lost -€3.800 (-10.670%).
Omnicell Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
As a result the target price of 47 € shows a positive potential of 47.8% compared to the current price of 31.8 € for Omnicell Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Omnicell Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Omnicell Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omnicell Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omnicell Inc. | -10.670% | -10.674% | -10.169% | 17.778% | -18.041% | -44.211% | -73.051% |
| Healthequity Inc. | -3.310% | 6.707% | 11.465% | 2.941% | 12.179% | 49.573% | 40.585% |
| Bruker Corp. | -3.550% | 2.445% | 3.417% | 61.758% | 33.562% | -13.524% | - |
| Myriad Genetics | 3.610% | -7.568% | -6.972% | 30.424% | -12.887% | -76.915% | -82.740% |
Comments
Omnicell (OMCL) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (OMCL) had its price target lowered by KeyCorp from $70.00 to $65.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (OMCL) had its "buy" rating reaffirmed by Craig Hallum.
Show more
Ratings data for OMCL provided by MarketBeat
News
Omnicell Q2 Earnings Call Highlights
Key Points
- Interested in Omnicell, Inc.? Here are five stocks we like better.
- Omnicell exceeded profitability expectations in Q2 2026, reporting $312 million in revenue, $67 million in
Investment Advisor Sells $6.6 Million Worth of Medical Solutions Stock, According to Recent SEC Filing
On April 29, 2026, Avory & Company, LLC disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 156,571 shares of Omnicell (NASDAQ:OMCL), an estimated $6.55 million
Why Omnicell Stock Trounced the Market on Tuesday
Omnicell (NASDAQ: OMCL) is off to a roaring start this year, at least as far as its quarterly performance is concerned. On Tuesday, it published its first earnings report of the year, and Mr. Market